What is Pharmagreen?
Pharmagreen Biotech Inc. operates at the intersection of advanced plant science and commercial agriculture. The company distinguishes itself through the deployment of its proprietary Chibafreen tissue culture process, which facilitates the production of high-quality starter plantlets for licensed cannabis cultivators and CBD/CBG hemp farmers. Beyond plant propagation, the firm provides critical value-added services, including DNA-based species identification and certification, alongside sophisticated live storage solutions for plant strains. By leveraging state-of-the-art greenhouse facilities, Pharmagreen ensures the delivery of premium flower tops, effectively bridging the gap between laboratory-grade genetic integrity and large-scale industrial production requirements.
How much funding has Pharmagreen raised?
Pharmagreen has raised a total of $10M across 1 funding round:
Private Equity
$10M
Private Equity (2019): $10M with participation from Oscaleta Partners LLC
Key Investors in Pharmagreen
Oscaleta Partners LLC
A private equity firm focused on identifying and scaling high-potential enterprises within the specialized biotechnology and agricultural sectors.
What's next for Pharmagreen?
The infusion of capital from this major strategic investment is expected to catalyze Pharmagreen's operational scaling and technological refinement. As the regulatory landscape for cannabis and hemp continues to evolve, the company is well-positioned to leverage its proprietary tissue culture technology to capture additional market share. Future strategic initiatives will likely focus on expanding greenhouse capacity and enhancing its suite of diagnostic services, thereby reinforcing its role as a foundational infrastructure provider for the global cannabinoid supply chain. The firm's commitment to genetic standardization and high-yield production remains the cornerstone of its long-term growth strategy.
See full Pharmagreen company page
